Denemek ALTIN - Özgür
"The ecosystem of Gujarat is ready to promote deep tech areas of biotech product development"
Bio Spectrum
|BioSpectrum Indian Feb 2025
ujarat has more than 200 biotechnology Gamers and a thriving startup ecosystem that includes prominent R&D and educational institutes. Gujarat's biotech sector generates more than Rs 12000 crore revenue and serves as an established biomanufacturing hub. Playing a key role in this direction is the Gujarat State Biotechnology Mission GSBTM) which has completed 20 years. The Government of Gujarat GoG) had established GSBTM in April 2004 under the Department of Science and Technology to facilitate the development of the biotech sector. In conversation with BioSpectrum, Manish Gurwani, Mission Director, Gujarat State Biotechnology Mission elaborates on how GSBTM’s latest biotechnology policy is transforming the sector in Gujarat. Edited excerpts:

How does the GSBTM plan to leverage infrastructure and incentives under the current policy to position the state as a globally competitive biotechnology hub?
Known for its entrepreneurship spirit, Gujarat has continued to be one of the preferred investment destinations for Ease of Doing Business (EoDB), Good Governance Index (GGI), Energy & Climate Index, Startup & LEADS ranking. The state contributes 40 per cent to India’s total cargo throughput with ~8.2 per cent in India’s GDP (as on FY2022-23 on current price). The state accounts for $12 billion (2023) with 8 per cent share of Bioeconomy, way above ~4 per cent state-wise average contribution of Bio-economy, amongst top 5 states of India in terms of Bio-economy contributors. This is the result of its top-class trunk and core infrastructure coupled with a safe and sound social environment in attracting top entrepreneurs from various parts of the country and abroad.
Gujarat showed great foresight, by setting up a dedicated mission office two decades ago, the Gujarat State Biotechnology Mission (GSBTM) followed by eco-system strengthening initiatives like Gujarat Biotechnology Research Centre (GBRC), Gujarat Biotechnology University (GBU) – Asia’s first ever dedicated biotechnology university and one of the top 5 public incubators Savli Technology and Business Incubator (STBI) with dedicated biotechnology parks for greenfield and brownfield spaces. These initiatives indicate Gujarat’s readiness to attract top biotech players in one of the thriving biotech ecosystems. GSBTM not only operates different schemes for facilitation of biotechnology, but is also the single window clearance office for all purposes, bringing in ease of doing business.
Bu hikaye Bio Spectrum dergisinin BioSpectrum Indian Feb 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum
India's Pharma Reforms Target Global Credibility
The Indian government has introduced several measures to simplify drug approvals and support innovation.
9 mins
October 2025

Bio Spectrum
How Waste Management Strategies Can Transform Indian Pharma Manufacturing
Sustainability will be a key success factor as India's pharmaceutical industry enters its next stage of expansion.
7 mins
October 2025

Bio Spectrum
IASST synthesises new compound to combat aggressive breast cancer
A newly designed nitro-substituted organoselenium compound by Guwahati-based Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science and Technology (DST), can reduce the invasiveness of aggressive triplenegative breast cancer cells by modulating various Se Se signalling pathways.
1 min
October 2025
Bio Spectrum
DPIIT signs MoU with Pfizer to strengthen healthcare innovation ecosystem
In a significant step towards strengthening India's healthcare innovation ecosystem, the Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry, has signed a Memorandum of Understanding (MoU) with Pfizer Limited.
1 min
October 2025

Bio Spectrum
WHO unveils updated guideline on HIV service delivery
WHO has released an updated guideline to support integrated HIV service delivery, promote long-term adherence to antiretroviral therapy (ART), and improve the overall health and well-being of people living with HIV.
1 min
October 2025
Bio Spectrum
Scientists in Kolkata explore therapeutic potential of accessory proteins
A hidden protein that protects our cells from mechanical stress could provide a new direction to therapeutic strategies for diseases where protein stability under force is compromised like heart muscle disease or genetic disorders called laminopathies.
1 min
October 2025

Bio Spectrum
US FDA advances rare disease drug development
The US Food and Drug Administration (FDA) has introduced the Rare Disease Evidence Principles (RDEP) to provide greater speed and predictability in the review of therapies intended to treat rare diseases with very small patient populations with significant unmet medical need and that are driven by a known genetic defect.
1 min
October 2025
Bio Spectrum
WHO updates list of essential medicines to include key cancer, diabetes treatments
The World Health Organization (WHO) has released updated editions of its Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLC), adding new treatments for various types of cancer and for diabetes with associated comorbidities such as obesity.
1 min
October 2025
Bio Spectrum
Agilent's MMR IHC Panel pharmDx (Dako Omnis) receives European IVDR Certification
Agilent Technologies Inc. has announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification under EU in vitro diagnostic regulation (IVDR)1 as a CDx test for colorectal cancer.
1 min
October 2025
Bio Spectrum
Aodh Lifesciences gets support from TDB to redefine pneumonia treatment
The Technology Development Board (TDB), Department of Science and Technology, Government of India, has extended support to Aodh Lifesciences, a startup based in Hyderabad, for development of Indigenous Antibiotic Nebulisation Suspension for Pneumonia (AONEUM-04) and Antimicrobial Resistance (AMR).
1 min
October 2025
Listen
Translate
Change font size